CDNA CAREDX INC

CareDx Brings the Transplant Patient Community Together

CareDx Brings the Transplant Patient Community Together

David Ayres joins a panel co-hosted by CareDx and National Kidney Foundation to talk about the impact of COVID-19 on the transplant community

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will be co-hosting a patient webinar with the National Kidney Foundation (NKF) and professional hockey player, and kidney transplant recipient, David Ayres on May 8, 2020, at 9:30am PST to discuss living with immunosuppression during COVID-19.

As a leading partner in transplant patient advocacy, CareDx has been working to help elevate conversations and provide resources to the transplant community about the COVID-19 pandemic through a series of patient events, including the with the NKF surrounding the changes in the transplant landscape in response to the coronavirus. The company is also working with TRIO (Transplant Recipients International Organization) and AAKP (American Association of Kidney Patients) on two upcoming virtual patient education events.

“As a kidney transplant recipient, I know first-hand that it can be challenging to deal with the effects and follow-up care without having to deal with coronavirus,” said Ayres. “While my transplant was back in 2004, I can only imagine that this pandemic makes it more difficult for these patients, and I am glad to work with CareDx and the NKF to share my experience in hopes that it helps others cope with what they are feeling and experiencing during these trying times.”

“Right now, the world is experiencing unprecedented disruption to every facet of life,” said Peter Maag, CEO of CareDx. “While our company remains steadfast in our commitment to drive innovation for patient care, we want to keep the transplant community connected – to foster conversations and provide additional insights for them as they navigate this new environment. We do not want anyone to be going through this alone.”

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

Investor Relations

Greg Chodaczek

347-620-7010

EN
07/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch